- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 8,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 198
- States / cities
- Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 13,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nephrotic Syndrome, Hyperlipidemia
- Interventions
- Atorvastatin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 1999
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Trauma
- Interventions
- Thromboelastometry guided transfusion
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 14 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
- Interventions
- Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- rosiglitazone, inhaled human insulin, metformin, glimepiride
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 103
- States / cities
- Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary artery bypass grafting, Percutaneous coronary intervention
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
- Conditions
- Peripheral Vascular Diseases
- Interventions
- Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 53
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 1356, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
- Conditions
- Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
- Interventions
- Patritumab deruxtecan, Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more
- Conditions
- Rosacea
- Interventions
- CLS001 (Omiganan), Vehicle
- Drug
- Lead sponsor
- Maruho Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 463 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Fremont, California • Miami, Florida • Miramar, Florida + 10 more
- Conditions
- Physical Activity, Breast Cancer
- Interventions
- Physical activity education, Facility access, Supervised exercise sessions, Self-monitoring (Fitbit), Active living counseling
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Limb-Threatening Ischemia
- Interventions
- Boomerang Catheter
- Device
- Lead sponsor
- Aveera Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 25
- States / cities
- San Bernardino, California • Sylmar, California • Torrance, California + 21 more
- Conditions
- Burns
- Interventions
- Enteral Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Daren K. Heyland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
- Conditions
- Breast Fat Grafting Retention
- Interventions
- AuraGen 1-2-3 with AuraClens
- Device
- Lead sponsor
- Tiger Biosciences, LLC.
- Industry
- Eligibility
- 22 Years to 65 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Miami, Florida + 10 more
- Conditions
- Cancer, Solid Tumors
- Interventions
- Vevorisertib, Fulvestrant, Paclitaxel
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Notapplicable
- Other
- Lead sponsor
- Actelion
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 105
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- SPN-810, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- natalizumab
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 44
- States / cities
- Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
- Conditions
- Alzheimer's Disease
- Interventions
- Elenbecestat, Placebo
- Drug
- Lead sponsor
- Eisai Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 2,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
- Interventions
- Famotidine, Celecoxib, Placebo
- Drug
- Lead sponsor
- Leidos Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-601, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
- Conditions
- Medical Oncology
- Interventions
- Anetumab ravtansine (BAY94-9343), Itraconazole
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
- Conditions
- Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
- Interventions
- Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
- Drug · Procedure
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
- Conditions
- Atherosclerosis
- Interventions
- Canakinumab, Placebo, Standard of care
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 315
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more